针对人体脂肪细胞脂解的小分子抑制剂
Gernot F Grabner1, Nikolaus Guttenberger2, Nicole Mayer2
1Institute of Molecular Biosciences, University of Graz, Heinrichstrasse 31/2, 8010 Graz, Austria.
Journal of the American Chemical Society
|April 1, 2022
概括
研究人员开发了第一种小分子脂肪三糖 lipase (ATGL) 抑制剂NG-497. 这种药物选择性地阻断ATGL活性,为胰岛素抵抗和心脏病等与脂质毒性相关的疾病提供潜在的治疗策略.
科学领域:
- 生物化学
- 药理学
- 代谢疾病
背景情况:
- 脂肪酸升高会导致脂肪毒性,损害非脂肪组织.
- 脂肪三糖 lipase (ATGL) 调节脂肪酸的释放,并与代谢障碍有关.
- 在治疗胰岛素耐药性,脂肪肝炎和心脏病方面,ATGL抑制是有前途的.
研究的目的:
- 开发和描述人类脂肪甘油三酶 (ATGL) 的第一个小分子抑制剂.
- 评估抑制剂的选择性和作用机制.
- 探索ATGL作为脂毒性驱动疾病的药物点.
主要方法:
- 开发一种新型小分子抑制剂NG-497.
- 人体脂肪细胞中NG-497的生物特征.
- 酶动力学,同质建模和化学ATGL蛋白质的分析以确定抑制剂-酶相互作用.
- 对相关的脂质酸酶进行种类选择性的评估.
主要成果:
- NG-497可以选择性地抑制人类和非人类灵长类的ATGL,而不是相关的水溶酶.
- 该抑制剂可依赖于剂量并可逆地消除人体脂肪细胞的脂解.
- 对ATGL抑制剂结合的详细了解揭示了对疗效和选择性负责的关键氨基酸残留物.
- NG-497与ATGL活性部位附近的疏水腔结合.
结论:
- NG-497是人类ATGL的第一个选择性小分子抑制剂.
- 这些发现证实ATGL是治疗脂质毒性和相关代谢疾病的可用标.
- 了解分子相互作用为开发更强效和选择性的ATGL抑制剂提供了支架.
相关概念视频
01:24Overview of Lipid Metabolism
2.8K
Lipid metabolism is a crucial process in the human body that involves the synthesis and degradation of lipids. This process is essential for energy production, cell membrane formation, and hormone production, among other functions.
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...
2.8K
01:24Glucagon-like Receptor Agonists
451
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
451